# Lanchun Duan

> Lanchun Duan is a Series C investor at Cathay Innovation backing Health Care and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Cathay Innovation](https://shizune.co/investors/profile/cathay-innovation-fund)
- Location: Shanghai, China
- Total investments: 6
- Last investment: Nov 2024
- Lead investor: 50%
- Last updated: Aug 2026

Lanchun Duan is a Series C investor at Cathay Innovation in Shanghai focused on Health Care and Medical. Lanchun is a Managing Partner of Cathay Capital, based in Shanghai.Lanchun joined Cathay Capital in 2010, and brings to the firm 10 years of audit and transaction services experience in China.Prior to Cathay Capital, Lanchun was an Associate Director with Deloitte & Touch Corporate Finance in China. In her role, she led the financialreview and valuation of M&A targets, and assisted with regulatory compliance and structures of deals, for many corporate and private equity firms. Representative clients included 3i, Blackstone, Carlyle, Merrill Lynch, SAIF Investment, Sumitomo, Shell, Iveco, Baosteel, China Resources, Jinjiang Group, Shanghai Auto Industrial Group.Previously, Lanchun was an Assistant Business Manager of Brian Jessel BMW in Vancouver, Canada. Prior to that, and out of undergraduate school, Lanchun spent 3 years as a Senior Accountant at PricewaterhouseCoopers in Beijing, where she performed IPO audits for large Chinese companies.Lanchun holds a bachelor degree in Accounting from the Central University of Finance and Economics in Beijing. She is also graduated from the Simon Fraser University Business School in Canada, and CEIBS in Shanghai (executive MBA).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Medical | 2 | 33% |
| Biotechnology | 2 | 33% |
| Biopharma | 1 | 17% |
| Life Science | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Angel | 1 | 17% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bio-Link | Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. |  | Venture - Series Unknown | Nov 11, 2024 |  |
| Bio-Link | Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. |  | Series A | Feb 21, 2024 |  |
| Huiying Medical | Huiying Medical specializes in the study, manufacturing, and international distribution of medical device technologies for tumor radiation. Its product matrix consists of intraoperative radiation, X-ray therapy, and high-dose brachytherapy products, all of which have received multi-national, FDA, and CE certifications. | $14.1M | Series B | Jan 08, 2024 |  |
| Weining Technology | Weining Technology offers digital risk control solutions and services for medical insurance and commercial health insurance. Its business covers intelligent monitoring of medical insurance, operation and management of medical insurance funds, intelligent risk control of commercial health insurance, reform of medical insurance payment methods, andperformance management of medical institutions. | $43.5M | Series C | Apr 24, 2023 |  |
| PackGene Biotech | PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, wedeliver cost-effective, dependable, and scalable production solutions. |  | Series C | Apr 07, 2021 |  |
| Shenfu Jianxing | Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems. | $44.2M | Angel |  |  |

6 of 6 investments shown.

## Co-investors
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [Haiwang Capital](https://shizune.co/investors/profile/haiwang-capital) — VC Fund, 2 deals together
- [Alwin Capital](https://shizune.co/investors/profile/alwin-capital) — VC Fund, 1 deal together
- [Asymchem Laboratories (Tianjin)](https://shizune.co/investors/profile/asymchem-laboratories-tianjin) — VC Fund, 1 deal together
- [Bloomage Healthcare Consumer Goods Industry Fund](https://shizune.co/investors/profile/bloomage-healthcare-consumer-goods-industry-fund) — VC Fund, 1 deal together

## About Cathay Innovation

VC Fund · San Francisco, United States

Cathay Innovation is a multistage venture capital firm affiliated with Cathay Capital, investing in founders building transformative businesses across Europe, North America, Asia, Latin America, and Africa. Its platform connects founders with investors and its ecosystem of leading Fortune 500 corporations to help startups scale and transformindustries with consumer-to-enterprise and AI solutions in commerce, fintech, digital health, and mobility/energy. Cathay Innovation now manages over €2.5B AUM with offices in Paris, Berlin, Madrid, San Francisco, Mexico City, Shanghai, and Singapore and has invested in over 150 startups, including Chime, Pinduoduo (NASDAQ: PDD), Glovo, Wallbox (NYSE: WBX), Owkin, Ledger, ZenBusiness, Alma, Descartes Underwriting, and more.

5 contacts available at Cathay Innovation.

| Name | Title | Profile |
| --- | --- | --- |
| Rajive Keshup | Partner | https://shizune.co/investors/profile/rajive-keshup |
| Costanza Carissimo | Director | https://shizune.co/investors/profile/costanza-carissimo |
| Denis Barrier | Co-founder and CEO | https://shizune.co/investors/profile/denis-barrier |
| Jacky Abitbol | Managing Partner | https://shizune.co/investors/profile/jacky-abitbol |
| John Li | Partner | https://shizune.co/investors/profile/john-li-1c00 |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Lanchun Duan invest in?

Lanchun Duan invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Angel stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lanchun Duan last invest?

The most recent investment recorded for Lanchun Duan closed in Nov 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co